The other aspect is in regards to pharmaceutical provision for mental health conditions, or even those in regards to paediatrics and children, and which allow them to have better outcomes in terms of their learning ability at school, or the fact that a mental health condition may restrict their ability either to work or to contribute in terms of society. Again, the way in which Pharmac assesses the benefit case for the investment regarding that pharmaceutical drug is solely restrained and constricted to the health sphere. In effect, when you stand back and look at it, you go, "Well, that doesn't feel right." That doesn't meet that litmus test around the fact that benefits don't just derive within a single bucket; they actually fall across other aspects of our system, and I think the Government have shown through the justice cluster that they've brought in in Budget 2022 a bit of an insight in terms of acknowledging that there are shared benefits across multiple sectors. 